World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
32
Citations
3999
World Ranking
9534
National Ranking
707

Overview

Lance A. Smith is affiliated with King's College London in the United Kingdom and specializes in the field of Medicine, with a particular focus on Oncology. Their research encompasses adjacent subfields such as Immunology, Radiology, Nuclear Medicine and Imaging, as well as Biomedical Engineering.

Their work predominantly revolves around topics including CAR-T cell therapy research, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers, Biosimilars and Bioanalytical Methods, Monoclonal and Polyclonal Antibodies Research, and Nanowire Synthesis and Applications.

Smith has contributed to several recent papers within reputable scientific journals. Notable publications include:

  • Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072, 2024, published in Blood
  • BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL, 2024, published in Blood
  • First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma, 2025, published in Neuro-Oncology Advances

Their research has appeared primarily in the journal Blood as well as Neuro-Oncology Advances.

Frequent collaborators include Martin Hutchings, Michael Dickinson, Giuseppe Gritti, Carmelo Carlo-Stella, and Natalie Dimier, all of whom have co-authored multiple publications with Smith.

Best Publications

  • Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.

    Tomoyuki Kanda;Michael J. Jackson;Lance A. Smith;Ronald K. B. Pearce

  • Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.

    Tomoyuki Kanda;Michael J. Jackson;Lance A. Smith;Ronald K.B. Pearce

  • Chronic L‐DOPA administration induces dyskinesias in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmoset (Callithrix jacchus)

    R. K. B. Pearce;M. Jackson;L. Smith;P. Jenner

  • A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets

    John W. Kebabian;Donald R. Britton;Michael P. DeNinno;Richard Perner

  • Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.

    Lance A. Smith;Michael J. Jackson;Ghassan Al‐Barghouthy;Sarah Rose

  • Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease

    Peter-Andreas Löschmann;Carmen De Groote;Lance Smith;Ullrich Wüllner

  • 3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates

    Mahmoud M. Iravani;Michael J. Jackson;Mikko Kuoppamäki;Lance A. Smith

  • Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure

    Lance A. Smith;Michael J. Jackson;Matthew J. Hansard;Eleni Maratos

  • Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.

    P. A. Löschmann;L. A. Smith;Klaus W. Lange;P. Jähnig

  • Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.

    Matthew J. Hansard;Lance A. Smith;Michael J. Jackson;Sharon C. Cheetham

  • The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.

    Sarah Rose;Michael J. Jackson;Lance A. Smith;Kim Stockwell

  • ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

    K. Shiosaki;P. Jenner;K. E. Asin;D. R. Britton

  • Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study

    Kanna K. Gnanalingham;Lance A. Smith;A. Jackie Hunter;Peter Jenner

  • A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.

    Mahmoud M. Iravani;Emilie Syed;Michael J. Jackson;Louisa C. Johnston

  • Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.

    Lance A. Smith;Michael J. Jackson;Louisa Johnston;Mikko Kuoppamaki

  • Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.

    Michael J. Jackson;Ghassan Al-Barghouthy;Ronald K.B. Pearce;Lance Smith

  • Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease

    Joanna Iczkiewicz;Michael J. Jackson;Lance A. Smith;Sarah Rose

  • Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset

    Kanna K. Gnanalingham;Lance A. Smith;Peter Jenner;Dilek D. Erol

  • Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation

    Lance A. Smith;Banu C. Tel;Michael J. Jackson;Matthew J. Hansard

  • S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole

    Mark J. Millan;Benjamin Di Cara;Michael Hill;Michael Jackson

  • Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets

    Smith La;Gordin A;Jenner P;Marsden Cd

  • Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates

    Unknown

Frequent Co-Authors

Charles David Marsden
Charles David Marsden King's College London
Markus Rudin
Markus Rudin ETH Zurich
Ullrich Wüllner
Ullrich Wüllner University Hospital Bonn

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring neuroscience in the USA opens doors to a variety of related professions and academic routes. For those interested in clinical practice, online psyd clinical psychology programs provide a flexible pathway to earn a doctoral degree, focusing on advanced clinical skills.

Many students opt for mft accredited programs to become Marriage and Family Therapists—an in-demand field closely aligned with neuroscience through its emphasis on mental health and behavioral science.

Those looking to enter the workforce quickly can benefit from accelerated degree programs. These intensive programs let you complete a bachelor’s faster, helping you start your career or grad school journey sooner.

When considering potential earnings, it’s wise to research the best bachelor degrees for high-paying jobs in science, healthcare, and psychology. By aligning your academic choices with these pathways, you can maximize both your passion for neuroscience and your future career prospects.

Best Scientists Citing Lance A. Smith

Recently Published Articles